Загрузка...
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
BACKGROUND: Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and efficacy analyses of this pooled dataset (n = 460). METHODS: Efficacy was...
Сохранить в:
| Опубликовано в: : | BMC Neurol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5427571/ https://ncbi.nlm.nih.gov/pubmed/28494751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-017-0867-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|